IONS IONIS PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2023 - Positive Study Results for Eplontersen in ATTRv-PN Patients Ionis Pharmaceuticals announced positive results from the Phase 3 NEURO-TTRansform study for eplontersen in patients with ATTRv-PN.Get access to all SEC 8-K filings of the IONIS PHARMACEUTICALS INC